Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $35.00 at Guggenheim

Arcutis Biotherapeutics (NASDAQ:ARQT) had its target price raised by research analysts at Guggenheim from $34.00 to $35.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective indicates a potential upside of 29.03% from the company’s previous close.

Other equities research analysts have also issued reports about the company. HC Wainwright increased their price target on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday. Wall Street Zen cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Zacks Research lowered shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Monday, December 29th. Finally, Mizuho upped their target price on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the company an “outperform” rating in a report on Friday, November 28th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Arcutis Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.14.

Arcutis Biotherapeutics Stock Down 5.1%

Shares of NASDAQ ARQT traded down $1.45 during mid-day trading on Friday, reaching $27.13. 487,158 shares of the company’s stock traded hands, compared to its average volume of 1,412,815. Arcutis Biotherapeutics has a 1-year low of $11.86 and a 1-year high of $31.77. The stock has a market cap of $3.32 billion, a P/E ratio of -193.74 and a beta of 1.70. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.50 and a quick ratio of 3.28. The business has a 50-day simple moving average of $27.26 and a 200 day simple moving average of $23.71.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.10. The firm had revenue of $129.50 million during the quarter, compared to analyst estimates of $110.79 million. Arcutis Biotherapeutics had a negative return on equity of 11.01% and a negative net margin of 4.29%. On average, analysts expect that Arcutis Biotherapeutics will post -1.33 EPS for the current fiscal year.

Insider Activity at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, Director Howard G. Welgus sold 10,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.05, for a total transaction of $250,500.00. Following the sale, the director owned 59,744 shares in the company, valued at $1,496,587.20. This represents a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Todd Watanabe sold 19,833 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $25.50, for a total value of $505,741.50. Following the sale, the insider owned 721,306 shares in the company, valued at approximately $18,393,303. This represents a 2.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 124,656 shares of company stock worth $3,312,365 in the last ninety days. Insiders own 9.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. increased its stake in Arcutis Biotherapeutics by 325.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after acquiring an additional 833 shares during the last quarter. Global Retirement Partners LLC bought a new position in shares of Arcutis Biotherapeutics in the 4th quarter worth $35,000. EverSource Wealth Advisors LLC raised its position in shares of Arcutis Biotherapeutics by 124.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after buying an additional 698 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Arcutis Biotherapeutics by 209.0% during the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock worth $45,000 after acquiring an additional 1,045 shares during the last quarter. Finally, Johnson Investment Counsel Inc. bought a new stake in shares of Arcutis Biotherapeutics during the 3rd quarter worth $30,000.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong Q4 / guidance raise — Q4 ZORYVE net product revenue was $127.5M (up 84% YoY); full‑year ZORYVE revenue $372.1M (+123% YoY). Management raised 2026 net product sales guidance to $480–$495M and reported positive operating cash flow, improving the company’s path to sustained profitability. Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Pediatric label catalyst — positive topline data from the INTEGUMENT‑INFANT Phase 2 trial for ZORYVE in ages 3–24 months and management’s plan to file an sNDA in Q2 2026 provide a near‑term regulatory/label expansion catalyst that could broaden prescribing. Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Analyst price target upgrades — TD Cowen raised its target to $35 (buy) and Needham raised its target to $36 (buy), signaling continued analyst confidence in sales momentum and longer‑term upside. TD Cowen Price Target Raise (Benzinga) Needham Price Target Raise
• Neutral Sentiment: Market commentary and transcripts — multiple analyst writeups and the earnings call transcript highlight ARQT’s transition to a high‑growth commercial company and outline pipeline strategy; useful for modeling but not new news. Seeking Alpha: Zoryve Dominance & Pipeline Catalysts
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates — the firm trimmed Q2, Q3 and Q4 2026 EPS forecasts (Q2: $0.02 from $0.06; Q3: $0.05 from $0.10; Q4: $0.19 from $0.30). Although HC Wainwright maintained a Buy rating and $34 target, the cuts reduce near‑term earnings expectations and likely contributed to downward price pressure.
• Neutral Sentiment: Short‑interest data appears inconsistent — recent short‑interest reports show 0 shares / NaN changes, indicating a data issue; no clear short squeeze or covering signal from the filings.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.